References
Maurel J, Reguard N. Optimal treatment for poor prognosis isolated colorectal carcinoma liver metastases. Rationality for prospective neodajuvant clinical trials. Rev Oncologia 2001; 3: 72–78.
Figueras J, Torras J, Valls C, et al. Factores pronóstico e indicaciones quirúrgicas en las metástasis hepáticas de carcinoma colorrectal. Rev Oncologia 2000; 2: 309–315.
Navarro M, Aranoe A, Zurita FJ, et al. The value of followup in resectable colorectal cancer after adjuvant therapy. Eur J Cancer 1999; 35 (suppl).
Bismuth E, Adam R, Levi T, et al. Resection of non-resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 214: 509–522.
Sorensen P, Edal Al, Madsen, et al. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluoracil. Cancer 1995; 75: 2.592–2.596.
Norum J. 5-fluoracil/levamisole induced intrahepatic fat infiltration. Acta Oncologica. 1995; 34: 971–972.
Selzner M. Clavien PA. Fatty liver in liver transplantation and surgery. Sem Liver Dis 2001; 21: 105–113.
Nordlinger B, Guiget M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection. Cancer 1996; 771: 1.254–1.262.
Figueras J, Torras J, Valls C, et al. Resección de metastasis hepáticas de carcinoma colorectal. Índice de resecabilidad y supervivencia a largo plazo. Cir Esp 2001, 70 (en prensa).
Rights and permissions
About this article
Cite this article
Figueras, J., Torras, J. & Serrano, T. Liver metastases in colorectal cancer. Rev Oncol 3, 278–279 (2001). https://doi.org/10.1007/BF02719891
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02719891